Tirzepatide: Identity, Evidence, and Documentation

Tirzepatide is cataloged here as a acylated dual gip/glp-1 receptor agonist peptide. Tirzepatide is an acylated peptide that activates the GIP and GLP-1 receptors. It is also the active ingredient in FDA-approved prescription products, but that fact does not make a separate research material an approved drug or a substitute for one.

Identity before interpretation

Finished FDA-approved medicines and a Vespera research material differ in manufacturing, formulation, controls, labeling, regulatory status, and intended use. Evidence for an approved finished drug cannot validate a separate catalog material.

A short catalog name is a starting point, not a complete material characterization. Reproducible work begins by matching the named material to its sequence or chemical form, SKU, lot, nominal quantity, analytical method, and the actual result reported for that sample.

Research questions in the literature

• Comparative GIP- and GLP-1-receptor pharmacology and signaling bias.
• Peptide engineering, albumin binding, and analytical differentiation from related agonists.
• How to separate published drug evidence from material identity and lot documentation.

These topics describe what investigators measured. They should not be converted into treatment language, consumer promises, or an assumption that a finding transfers across species, tissues, preparations, or experimental conditions.

Evidence map

• The 2018 discovery paper characterized LY3298176 across receptor assays, animal models, and an early clinical proof-of-concept study.
• Current FDA labeling identifies tirzepatide as a GIP- and GLP-1-receptor agonist in specific approved finished medicines.
• Neither source establishes the composition, quality, safety, effectiveness, or intended use of this Vespera catalog material.

Evidence strength depends on the question. A receptor assay can inform target engagement; a cell model can inform a pathway hypothesis; an animal model can inform a defined biological system. None of those alone proves clinical safety, effectiveness, or suitability of a separately sourced material.

Interpretation guardrails

• Do not transfer an approved product’s indications, dosing, administration, safety, or efficacy claims to a research material.
• Vespera does not offer a prescription medicine, compounded drug, generic, or substitute for an approved tirzepatide product.
• The live catalog title is preserved as production data; the scientific profile uses the accurate dual GIP/GLP-1 classification.

Vespera does not translate this literature into dosing, reconstitution, injection, route-of-use, diagnosis, treatment, or veterinary guidance. If a project requires those claims, this catalog and this brief are not the appropriate source.

Lot and COA review

• Match the exact catalog name, SKU, selected strength, lot, and analytical record.
• Review identity, mass, purity, quantity, and other method-specific results as separate questions.
• Keep all approved-drug labeling and clinical literature outside the procurement decision for a non-clinical research material.

Chromatographic purity, mass confirmation, quantity, endotoxin, microbial controls, residual solvents, water content, and stability answer different questions. A single headline percentage should not be used as a universal quality score.

Primary and official sources

Read the methods, model, material description, limitations, and conflicts of interest in the source itself.

1. Coskun et al. — LY3298176 discovery and receptor characterization (2018)Primary discovery and proof-of-concept paper.
2. FDA — current Zepbound prescribing informationOfficial labeling for an approved finished drug; not Vespera product documentation.
3. FDA — proposal concerning tirzepatide on the 503B bulks list (2026)Current compounding-policy context.